Journal Mobile Options
Table of Contents
Vol. 30, No. 2, 2007
Issue release date: April 2007
Section title: Original Paper
Kidney Blood Press Res 2007;30:124–128
(DOI:10.1159/000101448)

Treatment of Lupus Nephritis with Cyclosporine – An Outcome Analysis

Rihova Z.a · Vankova Z.a · Maixnerova D.a · Dostal C.b · Jancova E.a · Honsova E.c · Merta M.a · Rysava R.a · Tesař V.a
aNephrology Unit and bInstitute for Rheumatology, 1st Medical Faculty, Charles University, and cPathology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 2/13/2006
Accepted: 3/5/2007
Published online: 3/30/2007
Issue release date: April 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR

Abstract

Background: The optimal therapy for lupus nephritis (LN), including the role of cyclosporine (CsA), still lacks scientifically valid clinical experience. We evaluated the efficacy of CsA in the induction and maintenance treatment of patients with biopsy-proven LN. Patients and Methods: A total of 31 patients (25 women, 6 men, mean age 29.5 years) were enrolled in the study. The majority had proliferative LN. The mean follow-up was 85.6 ± 24.7 months. Results: CsA was used as first-line treatment in 38.7% of patients and as second-line treatment in 61.3% of patients. Complete remission was achieved in 93.5% of patients. The relapse rate was 45.2%. The mean disease-free interval was 33 months. At the end of follow-up, a total of 67.9% of the patients were in remission. The treatment led to significant improvement in proteinuria (p = 0.001) and stabilization of renal function. Conclusion: CsA might be an appropriate and a less toxic alternative drug for LN both as a first-choice and rescue therapy.

© 2007 S. Karger AG, Basel


  

Author Contacts

Zuzana Rihova, MD
Nephrology Unit, 1st Medical Faculty, Charles University
U Nemocnice 2
CZ–128 08 Prague 2 (Czech Republic)
Tel. +420 224 962 663, Fax +420 224 962 696, E-Mail zrihova@centrum.cz

  

Article Information

Supported by the grant IGA MZ CR 8444-3.

Received: February 13, 2006
Accepted after revision: March 5, 2007
Published online: March 30, 2007
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 4, Number of References : 16

  

Publication Details

Kidney and Blood Pressure Research

Vol. 30, No. 2, Year 2007 (Cover Date: April 2007)

Journal Editor: Wanner, C. (Würzburg)
ISSN: 1420–4096 (print), 1423–0143 (Online)

For additional information: http://www.karger.com/KBR


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 2/13/2006
Accepted: 3/5/2007
Published online: 3/30/2007
Issue release date: April 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.